# Inmune Bio, Inc.: overview INMB · Nasdaq · CIK 1711754 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/inmb.md) · [Financials](/companies/inmb/financials.md) · [Filings](/companies/inmb/filings.md) · [Insiders](/companies/inmb/insiders.md) Latest reported revenue: [$0](/filings/0001213900-26-036370.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 30, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-036370). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0 d](/filings/0001213900-25-104141.md) | [0.0 d](/filings/0001213900-26-036370.md) | [50.0](/filings/0001213900-26-053338.md) | [0.0 d](/filings/0001213900-26-086135.md) | [0.0 d](/filings/0001213900-25-104141.md) | [0.0 d](/filings/0001213900-26-036370.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(19810.0%)](/filings/0001213900-26-053338.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | [(19478.0%)](/filings/0001213900-26-086135.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.60)](/filings/0001213900-25-104141.md) | not reported | [(0.43)](/filings/0001213900-26-053338.md) | [(1.05)](/filings/0001213900-26-086135.md) | [(0.24)](/filings/0001213900-25-104141.md) | not reported | [(0.20)](/filings/0001213900-26-053338.md) | [(0.05)](/filings/0001213900-26-086135.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(5,632) d](/filings/0001213900-25-104141.md) | [(3,087) d](/filings/0001213900-26-036370.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001213900-23-016875.md) | [0.4](/filings/0001213900-24-027206.md) | [0.2](/filings/0001013762-25-003354.md) | [0.0](/filings/0001213900-26-036370.md) | [0.1](/filings/0001213900-26-036370.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(16106.6%)](/filings/0001213900-23-016875.md) | [(6938.8%)](/filings/0001213900-24-027206.md) | [(19187.7%)](/filings/0001013762-25-003354.md) | [(304535.7%)](/filings/0001213900-26-036370.md) | [(94766.0%)](/filings/0001213900-26-036370.md) | | Net margin | % | [(16762.4%)](/filings/0001213900-23-016875.md) | [(7299.2%)](/filings/0001213900-24-027206.md) | [(19360.0%)](/filings/0001013762-25-003354.md) | [(300585.7%)](/filings/0001213900-26-036370.md) | [(91866.0%)](/filings/0001213900-26-036370.md) | | Diluted EPS | $ per share | [(1.88)](/filings/0001213900-23-016875.md) | [(1.52)](/filings/0001213900-24-027206.md) | [(1.67)](/filings/0001013762-25-003354.md) | [(2.11)](/filings/0001213900-26-036370.md) | [(1.86)](/filings/0001213900-26-036370.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | [(23.6)](/filings/0001213900-26-036370.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inmb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.2m | 706,424 | | Added +19,409 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $1.1m | 662,218 | | Added +391,901 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $507.9k | 311,613 | | Reduced −882,499 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $347.2k | 212,995 | | Added +9,750 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $310.3k | 190,215 | | Reduced −304,754 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $301.9k | 185,245 | | Reduced −46,341 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $260.1k | 159,559 | | New +159,559 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $258.3k | 158,452 | | Reduced −35,939 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $218.8k | 134,232 | | Added +83,288 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $180.0k | 110,413 | | Reduced −142,927 | ## Recent filings [All 589 filings](/companies/inmb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 09:00 ET | [8-K](/filings/0001213900-26-111207.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-111207 | | 2026-09-14 | 16:05 ET | [8-K](/filings/0001213900-26-099700.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-099700 | | 2026-08-06 | 16:07 ET | [10-Q](/filings/0001213900-26-086135.md) | Quarterly report, period 2026-06-30 | 0001213900-26-086135 | | 2026-07-31 | 16:06 ET | [8-K](/filings/0001213900-26-083961.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-083961 | | 2026-07-01 | 07:16 ET | [8-K](/filings/0001213900-26-073983.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-073983 | | 2026-06-23 | 16:05 ET | [8-K](/filings/0001213900-26-071082.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-071082 | | 2026-06-17 | 16:01 ET | [8-K](/filings/0001213900-26-069611.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-069611 | | 2026-06-02 | 16:00 ET | [8-K](/filings/0001213900-26-064144.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-064144 | | 2026-05-14 | 16:05 ET | [8-K](/filings/0001213900-26-056599.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-056599 | | 2026-05-07 | 16:17 ET | [10-Q](/filings/0001213900-26-053338.md) | Quarterly report, period 2026-03-31 | 0001213900-26-053338 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036370.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1711754 - Tickers: INMB - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:41 ET. No prices; not investment advice.